Onyx multiple myeloma drug to face FDA advisory panel June 20

Onyx Pharmaceuticals Inc.’s cancer drug carfilzomib must face a Food and Drug Administration advisory committee, the company said Thursday. South San Francisco-based Onyx (NASDAQ: ONXX) said the FDA’s Oncologic Drugs Advisory Committee will meet June 20 to discuss carfilzomib, a drug aimed at patients with relapsed or refractory multiple myeloma who have received at least two prior therapies. The FDA, which is not required to follow the committee’s recommendation, is scheduled to make its decision on carfilzomib on July 27.